More on the Limitations of the Activated Partial Thromboplastin Time for Monitoring Argatroban Therapy
Explore this paper's citation graph
Summary
It is agreed that the activated partial thromboplastin time (aPTT) assay is the most commonly used method for monitoring patients on argatroban, and the opportunity to offer additional considerations on the use of aPTT, including its limitations is offered.
- Type
- article
- Published
- 2017-06-15
- Cited by
- 4
- References
- 13
- Access
- Open access
- OpenAlex
- https://openalex.org/W28618436
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:38551945
Keywords
Political science
References
- Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban
- The Pharmacokinetics and Pharmacodynamics of Argatroban: Effects of Age, Gender, and Hepatic or Renal Dysfunction
- Monitoring direct thrombin inhibitors with a plasma diluted thrombin time
- Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia
- Apparent Argatroban Resistance in a Patient with Elevated Factor VIII Levels
- Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial
- Alternative Monitoring of Argatroban Using Plasma-Diluted Thrombin Time
- Comparison of the ecarin chromogenic assay and different aPTT assays for the measurement of argatroban concentrations in plasma from healthy individuals and from coagulation factor deficient patients.
- Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?
- Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia
- Argatroban monitoring: aPTT versus chromogenic assay
- Further evidence of the limitations of Activated Partial Thromboplastin Time to monitor Argatroban
- Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors